JP2022529321A5 - - Google Patents

Info

Publication number
JP2022529321A5
JP2022529321A5 JP2021559729A JP2021559729A JP2022529321A5 JP 2022529321 A5 JP2022529321 A5 JP 2022529321A5 JP 2021559729 A JP2021559729 A JP 2021559729A JP 2021559729 A JP2021559729 A JP 2021559729A JP 2022529321 A5 JP2022529321 A5 JP 2022529321A5
Authority
JP
Japan
Prior art keywords
optionally substituted
compound according
formula
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559729A
Other languages
English (en)
Japanese (ja)
Other versions
JP7661235B2 (ja
JP2022529321A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029149 external-priority patent/WO2020219464A1/en
Publication of JP2022529321A publication Critical patent/JP2022529321A/ja
Publication of JP2022529321A5 publication Critical patent/JP2022529321A5/ja
Priority to JP2025060882A priority Critical patent/JP2025106352A/ja
Application granted granted Critical
Publication of JP7661235B2 publication Critical patent/JP7661235B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559729A 2019-04-22 2020-04-21 環状リン酸エステル化合物 Active JP7661235B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025060882A JP2025106352A (ja) 2019-04-22 2025-04-02 環状リン酸エステル化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837137P 2019-04-22 2019-04-22
US62/837,137 2019-04-22
PCT/US2020/029149 WO2020219464A1 (en) 2019-04-22 2020-04-21 Cyclic phosphate compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025060882A Division JP2025106352A (ja) 2019-04-22 2025-04-02 環状リン酸エステル化合物

Publications (3)

Publication Number Publication Date
JP2022529321A JP2022529321A (ja) 2022-06-21
JP2022529321A5 true JP2022529321A5 (https=) 2023-04-26
JP7661235B2 JP7661235B2 (ja) 2025-04-14

Family

ID=72941350

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559729A Active JP7661235B2 (ja) 2019-04-22 2020-04-21 環状リン酸エステル化合物
JP2025060882A Pending JP2025106352A (ja) 2019-04-22 2025-04-02 環状リン酸エステル化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025060882A Pending JP2025106352A (ja) 2019-04-22 2025-04-02 環状リン酸エステル化合物

Country Status (9)

Country Link
US (1) US20220220145A1 (https=)
EP (1) EP3966221A4 (https=)
JP (2) JP7661235B2 (https=)
KR (1) KR20210154229A (https=)
CN (1) CN113939526A (https=)
AU (1) AU2020263283B2 (https=)
CA (1) CA3136954A1 (https=)
MX (1) MX2021012894A (https=)
WO (1) WO2020219464A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102708995B1 (ko) 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
MX2022000573A (es) 2019-07-17 2022-02-10 Nucorion Pharmaceuticals Inc Compuestos ciclicos de desoxirribonucleotido.
JP2023523415A (ja) * 2020-04-21 2023-06-05 リガンド・ファーマシューティカルズ・インコーポレイテッド ヌクレオチドプロドラッグ化合物
WO2021216431A1 (en) * 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Benzyloxy phosph(on)ate compounds
EP4232456A4 (en) * 2020-10-21 2026-04-01 Ligand Pharm Inc COMPOUNDS OF ANTIVIRAL MEDICINES
WO2022245584A1 (en) * 2021-05-17 2022-11-24 Ligand Pharmaceuticals Incorporated Unnatural configuration nucleotide prodrug compounds
CN118005694B (zh) * 2023-01-06 2025-04-22 北京双鹤润创科技有限公司 一种环状核苷类似物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023120B2 (ja) * 1979-08-13 1985-06-05 キッコーマン株式会社 アデノシン−3′,5′−環状リン酸アルキルトリエステルの製造法
DE3027279A1 (de) * 1980-07-18 1982-05-06 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Substituierte adenosin-3',5'-phosphorsaeurebenzyltriester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5834436A (en) * 1993-04-09 1998-11-10 The Regents Of The University Of California Membrane-permeant second messengers
US5866548A (en) * 1993-04-09 1999-02-02 The Regents Of The University Of California Caged membrane-permeant inositol phosphates
US5693521A (en) * 1993-04-09 1997-12-02 The Regents Of The University Of California Membrane-permeant second messengers
WO2007027248A2 (en) * 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CA2819041A1 (en) * 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
US9296778B2 (en) * 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
EP2906579B1 (en) * 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
JP2016501200A (ja) * 2012-11-19 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. ウイルス性疾患を処置するための2−アルキニル置換ヌクレオシド誘導体
BR112015014457A2 (pt) * 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
US10202411B2 (en) * 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
EP3471737B1 (en) * 2016-06-20 2025-06-04 Merck Sharp & Dohme LLC Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
EP3661513A4 (en) 2017-07-31 2021-07-14 January Therapeutics, Inc. ORGANOPHOSPHATE DERIVATIVES
CN111801339B (zh) 2018-01-19 2025-06-24 纽科利制药公司 5-氟尿嘧啶化合物
US20210038628A1 (en) * 2018-03-02 2021-02-11 January Therapeutics, Inc. Nanoparticle compositions

Similar Documents

Publication Publication Date Title
JP2022529321A5 (https=)
CN109528721B (zh) 联合治疗
JP2020169171A5 (https=)
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
FI3518960T3 (fi) Annostusohjelma kontrolloidusti vapautuvalle PTH-yhdisteelle
RU97115713A (ru) Соединения, содержащие бензопиран и способ их применения
CN1129397A (zh) 治疗眼炎的含3-苯甲酰基苯乙酸衍生物的局部给药组合物
JP2022137237A5 (https=)
RU2004106555A (ru) Производные фенэтаноламина для лечения респираторных заболеваний
JP2002508302A (ja) 鎮痛薬として有用なα−アミノアミド誘導体
RU2012110380A (ru) Новое производное 5-фторурацила
JP2022527556A5 (https=)
JP2023546565A5 (https=)
JP2012525437A5 (https=)
JP2015535847A (ja) ケタミン誘導体
RU2005121927A (ru) Производные безводного кристаллического азидоцитозинполусульфата
RU2002101622A (ru) Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
RU2008131907A (ru) Новые соединения
JP2023522866A5 (https=)
JP2009507810A (ja) 自己免疫性疾患の処置
RU2011129771A (ru) Противораковые соединения
US4148911A (en) Method of treating respiratory disorders
RU2004109817A (ru) Производные аминопиррола в качестве противовоспалительных средств
RU2021129954A (ru) Циклические фосфатные соединения